Vernalis to re-acquire EU frovatriptan royalties; Isogenica gains rights to commercialize drugs with MRSA potential

15 February 2010

UK biotechnology firm Vernalis has announced the placing of £30 million ($46.3 million) in new shares to fund the reacquisition of European Union royalties on its antimigraine drug frovatriptan (trade name Frova) from Paul Capital, and to progress its development pipeline. This placing and transaction substantially strengthen Vernalis' cash position, ahead of IN STEP trial data in March, enabling the company to become debt free and to extend its cash runway beyond 2012, commented analysts at Edison Investment Research.

Vernalis will pay Paul Capital $32.57 million in cash and grant 2.1 million warrants in exchange for full economic rights to EU frovatriptan royalties from January 1, 2010. Following closure of the Paul Capital deal, Vernalis will be entitled to the entire royalty received from Italy's Menarini on EU frovatriptan sales from January 1 onwards. As Vernalis is also the supplier of the active pharmaceutical ingredient to Menarini, frovatriptan will become a 90% margin product for the UK company, up to its patent expiry in December 2015. Vernalis calculates that the product will generate an attractive 20% IRR over that period, based on undisclosed albeit conservative growth assumptions.

Results of indantadol program due in first half 2010

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology